Benefit of Erdosteine and Azithromycin Therapy in Preventing Exacerbations in Bronchiectasis (BEAT-BX Study) – A Long-term Comparative Efficacy Study

Technical Summary: The BEAT-BX Study

Problem Statement
Recurrent exacerbations in non-cystic fibrosis bronchiectasis (BE) are a primary driver of disease progression, leading to accelerated lung function decline, increased hospitalizations, and reduced quality of life. While long-term macrolide therapy (specifically azithromycin) is recommended for patients with frequent exacerbations due to its immunomodulatory and antimicrobial properties, concerns regarding antimicrobial resistance and long-term safety limit its universal application. Furthermore, abnormal airway mucus clearance—characterized by excessive viscosity and impaired mucociliary transport—sustains chronic infection and inflammation. While mucolytics like erdosteine have shown benefits in COPD, evidence supporting their long-term use in bronchiectasis, particularly in combination with macrolides, remains limited. The BEAT-BX study addresses the need for a multimodal strategy that simultaneously targets chronic airway infection, mucus retention, and inflammation to prevent recurrent exacerbations.

Methodology
The BEAT-BX (Benefit of Erdosteine and Azithromycin Therapy in Bronchiectasis) study was a prospective, randomized, multicenter, comparative observational study conducted in India between March 2024 and February 2025.

• Population: 158 adult patients with HRCT-confirmed non-cystic fibrosis bronchiectasis, a Modified Reiff Score >10, and a history of ≥3 exacerbations in the preceding 12 months. Patients were enrolled after recovering from an acute exacerbation.
• Intervention: Participants were randomized 1:1 into two groups:
  1. Combination Therapy: Oral azithromycin (500 mg three times weekly for one month, then 250 mg three times weekly) plus erdosteine (300 mg twice daily).
  2. Standard Care: Bronchodilators and airway clearance techniques only (no mucolytics or long-term macrolides).
• Follow-up: Patients were monitored for 36 weeks with monthly assessments of clinical status, sputum rheology, microbiology, spirometry, and adverse events.
• Outcomes: Primary outcomes included exacerbation frequency, severity (categorized by FACED/BSI), and duration. Secondary outcomes included time to first exacerbation, exacerbation-free days, and improvements in sputum rheological properties (viscosity, volume, color, clearance). Safety was assessed via gastrointestinal, hepatic, auditory, and systemic adverse events.
• Analysis: Statistical analysis utilized Independent Samples Student's t-tests for continuous variables and Pearson Chi-square tests for categorical variables, with a significance threshold of p < 0.05.

Key Contributions and Results
The study demonstrated that the combination of erdosteine and azithromycin provided significant clinical advantages over standard care across multiple domains:

• Exacerbation Severity and Frequency: The combination group experienced a significant reduction in severe exacerbations (12 episodes vs. 31 in the standard care group; p = 0.0018), representing a 61% reduction. While mild exacerbations were more frequent in the combination group (29 vs. 17), the overall shift indicated a reduction in disease severity.
• Recovery Time: Exacerbation duration was significantly shorter in the combination group across all severity levels:
  • Mild: 4.20 days vs. 7.29 days (p < 0.0001).
  • Moderate: 6.76 days vs. 11.15 days (p < 0.0001).
  • Severe: 8.83 days vs. 12.58 days (p < 0.0001).
    This represents a 31–44% reduction in recovery time.
• Time to Recurrence and Exacerbation-Free Days: The mean time to the first exacerbation was prolonged, particularly for severe episodes (129.25 days vs. 72.29 days; p < 0.0001). Exacerbation-free days were significantly higher in the combination group, with a 95% increase in severe disease (173 days vs. 77.96 days).
• Sputum Rheology: The combination therapy yielded marked improvements in sputum characteristics compared to standard care:
  • Improved viscosity and clearance: 78.48% vs. 27.84%.
  • Reduced sputum volume: 84.81% vs. 13.92%.
  • Improved sputum color: 87.34% vs. 17.72%.
    All rheological improvements were statistically significant (p < 0.00001).
• Microbiological Context: The study cohort had a high burden of multidrug-resistant Gram-negative pathogens, with Pseudomonas aeruginosa being the most common (30.37%) and showing 66.66% resistance. The benefits of the combination therapy were observed despite this high resistance burden.
• Safety: No serious gastrointestinal, auditory, or systemic adverse events requiring treatment discontinuation were reported in either group over the 36-week period.

Significance and Claims
The authors claim that the BEAT-BX study provides prospective real-world evidence supporting the use of long-term oral erdosteine combined with azithromycin as a safe and effective maintenance strategy for patients with recurrent exacerbation-prone non-cystic fibrosis bronchiectasis.

The study posits that the observed benefits arise from a synergistic mechanism: azithromycin suppresses neutrophilic inflammation and bacterial virulence, while erdosteine reduces mucus viscosity, enhances mucociliary clearance, and improves antibiotic penetration into bronchial secretions. This multimodal approach effectively targets the "vicious vortex" of chronic infection, mucus retention, and oxidative stress.

The authors conclude that this combination represents a cost-effective strategy that not only reduces the frequency and severity of exacerbations but also significantly improves sputum rheology and extends exacerbation-free intervals. They emphasize that these clinical benefits were achieved without significant toxicity, even in a population with high rates of multidrug-resistant organisms. However, the authors maintain a modest stance, noting that while the results are promising, larger multicenter randomized controlled trials with longer follow-up are necessary to validate these findings, determine optimal therapy duration, and further assess the long-term impact on antimicrobial resistance.